Automated and closed CTS DynaCellect Magnetic Separation System delivers target T cell isolation and magnetic bead removal at high efficiency

Successful commercial manufacturing of T cell therapies is essential to assuring the timely delivery of efficacious products to patients. Adequate cell therapy workflows have been developed to support clinical trials and commercialized T cell therapies. However, the industry faces several key barriers that limit the capability to deliver the required volume of high-quality product for autologous therapies and developing allogeneic applications.